H. Jeffrey Wilkins, M.D., has been appointed to the newly created position of chief medical officer, Lycera Corp. Dr. Wilkins will lead the development of a pipeline of immune modulators, including an ATPase modulator being developed to treat inflammatory bowel disease, and an RORgamma agonist for immuno-oncology applications. Both are scheduled to enter clinical trials this year. Dr. Wilkins will report to president and chief executive officer Paul Sekhri.   Most recently, Dr. Wilkins served as...